An immunotoxin incorporating an anti-programmed-cell-death-protein-1 (PD-1) single-chain variable fragment selectively eliminates PD-1-expressing cells, and suppresses autoimmunity while preserving adaptive immunity in mouse models of autoimmune disease.
Honigberg, L. A. et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.
Administration of the immunotoxin to mouse models of autoimmune diabetes delays disease onset, and its administration in mice paralysed by experimental autoimmune encephalomyelitis ameliorates symptoms.
It is clear that specific antigen vaccination is effective in preventing several animal models of autoimmune disease, and in treating these diseases once the symptoms are overt.
Here we review mouse models of autoimmune gastritis and their relevance to human autoimmune gastritis associated with pernicious anemia.
Increasing evidence supports the efficacy of this approach in pre-clinical models of autoimmune disease and allograft rejection.
Most recently, several groups have applied non-myeloablative or reduced-intensity conditioning protocols for allo-HCT to the induction of transplantation tolerance and re-establishment of self-tolerance in animal models of autoimmune disease.
Galectin-1, a mammalian lectin that modulates T cell function and apoptosis, has been shown to be immunomodulatory in animal models of autoimmune disease.
Green tea and its active ingredient, epigallocatechin-3-gallate (EGCG), have been shown to improve symptoms and reduce the pathology in some animal models of autoimmune diseases.
However, the anti-inflammatory activity of sialylated IgG has not been reproduced in some mouse models of autoimmune diseases.
A number of potent small molecule inhibitors of Kv1.3 channel have been reported, some of which were found to be effective in various animal models of autoimmune diseases.
